![]() ![]() Q: How does sacubitril–valsartan compare to valsartan regarding the composite outcome of total hospitalizations and cardiovascular death in patients with heart failure and preserved ejection fraction?Ī: In the PARAGON-HF trial, the primary composite outcome of total hospitalizations for heart failure and death from cardiovascular causes did not differ significantly between the two groups. In patients with heart failure and preserved left ventricular ejection fraction, sacubitril–valsartan resulted in a lower level of N-terminal pro–B-type natriuretic peptide, a larger reduction in left atrial size, and greater improvement in the NYHA functional class than valsartan. ![]() Clinical Pearls Q: Is sacubitril–valsartan effective in patients with heart failure and reduced ejection fraction?Ī: The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan resulted in a lower rate of hospitalization for heart failure or death from cardiovascular causes than enalapril among patients with heart failure and reduced ejection fraction (≤40%). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
January 2023
Categories |